StockNow
Log in
U.S. Markets

Vertex (VRTX) announces positive week 36 interim analysis results for primary and all secondary endpoints in the rainier phase 3 trial of povetacicept in adults with IGA nephropathy

News detail

To complete BLA for povetacicept by end of March for potential U.S. accelerated approval. Povetacicept was generally safe and well tolerated

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLYGeopolitics

Pakistani sources say Pakistan PM Sharif and Army Chief Munir will visit Saudi Arabia tomorrow, Al Hadath reports

U.S. Economy

US ADP Employment Change (Jul) 44K vs. Exp. 70K (Prev. 98K)